Star Equity (STRR) Competitors $2.72 +0.59 (+27.51%) Closing price 08/21/2025 08:00 PM EasternExtended Trading$2.72 0.00 (0.00%) As of 08/21/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock STRR vs. VVOS, COCH, PETV, RVP, ICU, FEMY, IRIX, DRIO, NXGL, and NRXSShould you be buying Star Equity stock or one of its competitors? The main competitors of Star Equity include Vivos Therapeutics (VVOS), Envoy Medical (COCH), PetVivo (PETV), Retractable Technologies (RVP), SeaStar Medical (ICU), Femasys (FEMY), IRIDEX (IRIX), DarioHealth (DRIO), NexGel (NXGL), and NeurAxis (NRXS). These companies are all part of the "medical equipment" industry. Star Equity vs. Its Competitors Vivos Therapeutics Envoy Medical PetVivo Retractable Technologies SeaStar Medical Femasys IRIDEX DarioHealth NexGel NeurAxis Star Equity (NASDAQ:STRR) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability. Which has better valuation and earnings, STRR or VVOS? Star Equity has higher revenue and earnings than Vivos Therapeutics. Star Equity is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStar Equity$67.39M0.13-$10.44M-$1.02-2.66Vivos Therapeutics$14.39M2.19-$11.14M-$1.68-2.50 Which has more volatility & risk, STRR or VVOS? Star Equity has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.03, meaning that its share price is 603% more volatile than the S&P 500. Does the media refer more to STRR or VVOS? In the previous week, Vivos Therapeutics had 3 more articles in the media than Star Equity. MarketBeat recorded 7 mentions for Vivos Therapeutics and 4 mentions for Star Equity. Star Equity's average media sentiment score of 0.20 beat Vivos Therapeutics' score of -0.09 indicating that Star Equity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Star Equity 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vivos Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders have more ownership in STRR or VVOS? 3.8% of Star Equity shares are held by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are held by institutional investors. 33.5% of Star Equity shares are held by insiders. Comparatively, 3.0% of Vivos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is STRR or VVOS more profitable? Star Equity has a net margin of -3.19% compared to Vivos Therapeutics' net margin of -99.49%. Star Equity's return on equity of 12.87% beat Vivos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Star Equity-3.19% 12.87% 5.01% Vivos Therapeutics -99.49%-232.76%-84.30% Do analysts recommend STRR or VVOS? Star Equity currently has a consensus target price of $5.00, suggesting a potential upside of 84.09%. Vivos Therapeutics has a consensus target price of $4.82, suggesting a potential upside of 14.68%. Given Star Equity's higher possible upside, research analysts plainly believe Star Equity is more favorable than Vivos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Star Equity 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Vivos Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryStar Equity beats Vivos Therapeutics on 9 of the 16 factors compared between the two stocks. Get Star Equity News Delivered to You Automatically Sign up to receive the latest news and ratings for STRR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STRR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STRR vs. The Competition Export to ExcelMetricStar EquityDIVERSIFIED OPS IndustryMulti-Sector SectorNASDAQ ExchangeMarket Cap$6.89M$16.11B$14.79B$9.62BDividend YieldN/A4.23%4.00%4.10%P/E Ratio-2.6612.4010.2326.05Price / Sales0.136.515.38193.75Price / Cash6.5338.2836.3358.48Price / Book0.2419.3516.406.61Net Income-$10.44M$951.86M$922.56M$265.65M7 Day Performance27.51%2.42%1.88%2.02%1 Month Performance24.02%-1.90%-2.23%-0.31%1 Year Performance-36.28%4.04%1.99%19.06% Star Equity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STRRStar Equity2.6742 of 5 stars$2.72+27.5%$5.00+84.1%-36.1%$6.89M$67.39M-2.66460News CoverageHigh Trading VolumeVVOSVivos Therapeutics1.3064 of 5 stars$4.36-2.1%$4.82+10.5%+59.1%$26.42M$15.03M-2.59160News CoverageEarnings ReportGap DownCOCHEnvoy Medical3.0416 of 5 stars$1.21-10.7%$9.25+667.0%-58.3%$26.15M$222K-0.8534Gap UpPETVPetVivoN/A$0.87+5.4%N/A+54.5%$24.25M$1.05M-1.9320Gap DownRVPRetractable Technologies1.8413 of 5 stars$0.79-0.8%N/A-12.9%$23.77M$38.16M-1.47240Positive NewsICUSeaStar Medical0.091 of 5 stars$0.77-6.8%N/A-87.5%$21.58M$140K-0.302FEMYFemasys3.2362 of 5 stars$0.66-6.3%$7.33+1,017.9%-43.5%$21.37M$1.63M-0.7630Gap UpIRIXIRIDEX1.5607 of 5 stars$1.17+0.1%N/A-36.3%$19.90M$48.67M-3.55120DRIODarioHealth1.2585 of 5 stars$0.43-4.0%$2.00+363.0%-37.4%$19.66M$27.04M-0.65200NXGLNexGel1.116 of 5 stars$2.35+1.7%N/A-16.2%$18.96M$8.69M-5.8710Gap UpNRXSNeurAxis2.6724 of 5 stars$2.37-4.4%$7.00+195.4%-20.8%$17.10M$3.22M-1.2919 Related Companies and Tools Related Companies Vivos Therapeutics Competitors Envoy Medical Competitors PetVivo Competitors Retractable Technologies Competitors SeaStar Medical Competitors Femasys Competitors IRIDEX Competitors DarioHealth Competitors NexGel Competitors NeurAxis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STRR) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Star Equity Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Star Equity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access